Kurve Technology and Schering-Plough Sign Expanded Technology Agreement

BOTHELL, Wash. and KENILWORTH, N.J., June 11, 2007 /PRNewswire-FirstCall/ -- Kurve Technology, Inc., a leading developer of nasal drug delivery devices, and Schering-Plough Corporation , a global science-based health care company, today announced a new agreement that expands Schering-Plough's evaluation of, and option for exclusivity rights to, Kurve Technology's Controlled Particle Dispersion(R) platform from a single field to multiple fields of use.

"We are extremely pleased with Schering-Plough's continued and expanded interest in our nasal delivery technology platforms," said Marc Giroux, Chairman and Chief Executive Officer of Kurve Technology, Inc. "This agreement is another significant step in our efforts of working with pharmaceutical companies to develop the most innovative intranasal drug/device combinations in the industry."

Kurve Technology's Controlled Particle Dispersion(R) (CPD) contains six critical-to-function design parameters that enable modification of deposition and droplet characteristics. The result is a flexible intranasal technology platform that can deliver virtually any liquid drug - solution or suspension - regardless of formulation characteristics including viscocity, surface tension or molecule size. CPD enables pharmaceutical companies to deliver topical, systemic, nose-to-brain drugs and vaccines with minimal peripheral deposition to the lungs and stomach. CPD powers Kurve Technology's ViaNase(TM) electronic atomizer line.

About Kurve Technology, Inc.

Kurve Technology, Inc. offers pharmaceutical companies innovative nasal delivery technologies for topical, systemic, nose-to-brain medical and vaccine therapies. Kurve's Controlled Particle Dispersion (CPD)(TM) technology intranasally delivers formulations with far greater efficacy and efficiency than traditional methods. The ViaNase product line of intelligent atomizers incorporates CPD with the potential to deliver a wide range of formulations. Kurve Technology is headquartered in Bothell, WA with offices in Research Triangle Park, NC and the United Kingdom. For additional information, please visit www.kurvetech.com.

About Schering-Plough Corporation

Schering-Plough Corporation is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 33,500 people around the world. The company's Web site is www.scheringplough.com.

43-0607

CONTACT: Media, Christine Slocumb of Kurve Technology, +1-425-984-6617,, or Fred Malley of Schering-Plough Corporation,+1-908-298-7428; or Investors, Alex Kelly of Schering-Plough Corporation,+1-908-298-7436 cslocumb@kurvetech.com

Web site: http://www.kurvetech.com/http://www.scheringplough.com//

Ticker Symbol: (NYSE:SGP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: June 2007


View comments

Hide
(web3)